Champlain Investment Partners LLC Lowers Stock Position in Agilent Technologies, Inc. $A

Key Points

• Champlain Investment Partners LLC has reduced its stake in Agilent Technologies by 7.5% during the first quarter, now holding 691,850 shares worth approximately $80.9 million.
• Other hedge funds have shown mixed activity, with some increasing their positions, including Brighton Jones LLC, which grew its stake by 6.1% to own 4,663 shares.
• Agilent Technologies reported a better-than-expected earnings performance with an EPS of $1.31, exceeding estimates, along with a year-over-year revenue increase of 6.0% to $1.67 billion.

Champlain Investment Partners LLC cut its holdings in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 7.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 691,850 shares of the medical research company's stock after selling 56,350 shares during the period. Champlain Investment Partners LLC owned 0.24% of Agilent Technologies worth $80,933,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of A. Brighton Jones LLC grew its position in shares of Agilent Technologies by 6.1% during the fourth quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company's stock worth $626,000 after acquiring an additional 270 shares during the last quarter. Integrated Wealth Concepts LLC grew its position in shares of Agilent Technologies by 24.5% during the fourth quarter. Integrated Wealth Concepts LLC now owns 3,413 shares of the medical research company's stock worth $458,000 after acquiring an additional 671 shares during the last quarter. Kovitz Investment Group Partners LLC purchased a new position in shares of Agilent Technologies during the fourth quarter worth approximately $699,000. Coldstream Capital Management Inc. grew its position in shares of Agilent Technologies by 11.6% during the fourth quarter. Coldstream Capital Management Inc. now owns 4,999 shares of the medical research company's stock worth $672,000 after acquiring an additional 520 shares during the last quarter. Finally, Northern Trust Corp grew its position in shares of Agilent Technologies by 12.3% during the fourth quarter. Northern Trust Corp now owns 4,192,790 shares of the medical research company's stock worth $563,259,000 after acquiring an additional 457,713 shares during the last quarter.

Insider Activity at Agilent Technologies

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,508 shares of the business's stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total transaction of $177,099.52. Following the sale, the chief executive officer directly owned 37,448 shares in the company, valued at approximately $4,397,893.12. The trade was a 3.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Agilent Technologies Price Performance

Shares of NYSE A opened at $118.44 on Wednesday. The firm has a market capitalization of $33.64 billion, a P/E ratio of 29.24, a PEG ratio of 3.62 and a beta of 1.22. Agilent Technologies, Inc. has a one year low of $96.43 and a one year high of $153.84. The company's fifty day moving average is $117.93 and its two-hundred day moving average is $116.88. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.60 and a current ratio of 2.09.

Agilent Technologies (NYSE:A - Get Free Report) last issued its earnings results on Wednesday, May 28th. The medical research company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.26 by $0.05. The company had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.63 billion. Agilent Technologies had a net margin of 17.59% and a return on equity of 25.92%. The business's revenue was up 6.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.22 EPS. Analysts forecast that Agilent Technologies, Inc. will post 5.58 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on A shares. TD Cowen raised their target price on shares of Agilent Technologies to $150.00 and gave the stock a "buy" rating in a research report on Thursday, May 29th. Wall Street Zen upgraded shares of Agilent Technologies from a "hold" rating to a "buy" rating in a research note on Saturday, June 28th. Robert W. Baird lowered their target price on shares of Agilent Technologies from $159.00 to $140.00 and set an "outperform" rating on the stock in a report on Thursday, May 22nd. JPMorgan Chase & Co. lowered their target price on shares of Agilent Technologies from $160.00 to $155.00 and set an "overweight" rating on the stock in a report on Thursday, May 29th. Finally, Barclays lifted their target price on shares of Agilent Technologies from $115.00 to $125.00 and gave the company an "equal weight" rating in a report on Tuesday, June 24th. Six equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, Agilent Technologies presently has a consensus rating of "Moderate Buy" and an average price target of $138.83.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.